{"id":"pemetrexed-disodium-f-injection","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Mucositis"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed disodium is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, key enzymes in the folate pathway required for purine and pyrimidine synthesis. By blocking these enzymes, it prevents DNA and RNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. It is typically administered with folic acid and vitamin B12 supplementation to reduce toxicity to normal tissues.","oneSentence":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:37.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Mesothelioma"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT02607423","phase":"PHASE2","title":"Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-11-19","conditions":"Stage IIIA Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04439890","phase":"PHASE3","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-08-08","conditions":"Advanced Non-squamous Cell Non-small Cell Lung Cancer","enrollment":369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pemetrexed disodium f Injection","genericName":"Pemetrexed disodium f Injection","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells. Used for Non-small cell lung cancer (NSCLC), Mesothelioma, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}